Evidence mapPaperPMID 42237378Full record

ReviewJournal of nanobiotechnology2026

From LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery.

Wenlin Wu, Zhigong Wei, Xingchen Peng

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wenlin WuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhigong WeiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China. weizg10@wchscu.edu.cn.
Xingchen PengDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China. pxx2014@163.com.

Funding

1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University ZYYC23006Clinical Research Incubation Project of West China Hospital 23HXFH001Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China, the Institutional Joint Innovation Fund from Sichuan University and Nuclear Power Institute of China 1-KJ-FWHT-WU-20240150Health Research Project of Chengdu Eastern New Area Management Committee 202304International Science and Technology Cooperation Program of Chengdu Science and Technology Bureau 2024-YF06-00011-HZNational Natural Sciences Foundation of China 82473434Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0503000Regional Innovation and Development Joint Fund Key Project of the National Natural Science Foundation of China U24A20735Science and Technology Project of Sichuan Provincial Health Commission Clinical Research Special Project JH2023082Sichuan Provincial Science and Technology Department Key Research and Development Program 2025YFHZ0151the Ministry of Education University-Industry Collaborative Education Program 230720523707281Yunnan Province Key Laboratory of Precision Diagnosis and Treatment for Thoracic Diseases 202449CE340026
6 · The paper itself

Abstract

Gene therapy has become a cornerstone of precision medicine, offering potential solutions for a wide spectrum of disorders at the molecular origin. However, the clinical performance of gene therapeutics is critically determined by the efficiency and safety of delivery vectors. Though viral vectors are widely used in gene therapy because of their high delivery efficiency, the safety concern remains a major limitation. In contrast, non-viral vectors have attracted increasing attention owing to their favorable safety profiles, structural tunability, larger cargo capacity, and scalable production. In this review, we examine five major classes of non-viral gene delivery vectors, including Lipid Nanoparticles (LNP), polyplexes, lipoplexes, and exosomes, together with their corresponding hybrid systems. For each platform, we summarize structural features, delivery mechanisms, therapeutic applications, and translational challenges, and further discuss how hybrid architectures integrate complementary properties from different vectors to overcome limitations inherent to single-component systems. By organizing these delivery strategies within a unified structure-function-application framework, this review provides an integrated perspective on non-viral vector design and highlights hybrid systems as an increasingly important direction for the optimization of clinically relevant gene delivery platforms.

Indexed as

Gene Transfer TechniquesLipidsNanoparticlesAnimalsExosomesGenetic TherapyGenetic VectorsHumansLiposomesLipid NanoparticlesLipidsLiposomesExosomesHybrid vectorsLipid Nanoparticles (LNP)LipoplexesNon-viral vectorsPolyplexes

Identifiers

PMID42237378
PMCPMC13450228

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.